These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2579551)

  • 1. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival.
    Ihde DC; Matthews MJ; Makuch RW; McIntire KR; Eddy JL; Seeff LB
    Am J Med; 1985 Mar; 78(3):399-406. PubMed ID: 2579551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy of hepatocellular carcinoma with doxorubicin and streptozotocin.
    Morstyn G; Ihde DC; Eddy JL; Bunn PA; Cohen MH; Minna JD
    Am J Clin Oncol; 1983 Oct; 6(5):547-51. PubMed ID: 6310986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
    Leung TW; Tang AM; Zee B; Yu SC; Lai PB; Lau WY; Johnson PJ
    Cancer; 2002 Jan; 94(2):421-7. PubMed ID: 11905412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrolamellar hepatocellular carcinoma in an infant and literature review.
    Cruz O; Laguna A; Vancells M; Krauel L; Medina M; Mora J
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):968-71. PubMed ID: 19131794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrolamellar hepatocellular carcinoma in children and adolescents.
    Katzenstein HM; Krailo MD; Malogolowkin MH; Ortega JA; Qu W; Douglass EC; Feusner JH; Reynolds M; Quinn JJ; Newman K; Finegold MJ; Haas JE; Sensel MG; Castleberry RP; Bowman LC
    Cancer; 2003 Apr; 97(8):2006-12. PubMed ID: 12673731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma.
    Nagahama H; Okada S; Okusaka T; Ishii H; Ikeda M; Nakasuka H; Yoshimori M
    Jpn J Clin Oncol; 1997 Oct; 27(5):321-4. PubMed ID: 9390209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
    Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
    J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy.
    Okada S; Okazaki N; Nose H; Yoshimori M; Aoki K
    Hepatology; 1992 Jul; 16(1):112-7. PubMed ID: 1377657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience.
    Weeda VB; Murawski M; McCabe AJ; Maibach R; Brugières L; Roebuck D; Fabre M; Zimmermann A; Otte JB; Sullivan M; Perilongo G; Childs M; Brock P; Zsíros J; Plaschkes J; Czauderna P; Aronson DC
    Eur J Cancer; 2013 Aug; 49(12):2698-704. PubMed ID: 23683550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the peripheral blood absolute monocyte count in patients with locally advanced or metastatic hepatocellular carcinoma receiving systemic chemotherapy.
    Lin GN; Jiang XM; Peng JW; Xiao JJ; Liu DY; Xia ZJ
    Asian Pac J Cancer Prev; 2014; 15(15):6387-90. PubMed ID: 25124630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy.
    Choi TK; Lee NW; Wong J
    Cancer; 1984 Feb; 53(3):401-5. PubMed ID: 6198058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history.
    Epstein BE; Pajak TF; Haulk TL; Herpst JM; Order SE; Abrams RA
    Am J Clin Oncol; 1999 Feb; 22(1):22-8. PubMed ID: 10025374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center.
    Abrams RA; Pajak TF; Haulk TL; Flam M; Asbell SO
    Cancer J Sci Am; 1998; 4(3):178-84. PubMed ID: 9612600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
    Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
    Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adriamycin and cisplatin for hepatoblastoma.
    Quinn JJ; Altman AJ; Robinson HT; Cooke RW; Hight DW; Foster JH
    Cancer; 1985 Oct; 56(8):1926-9. PubMed ID: 2411381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatocellular carcinoma arising in the normal liver. A clinical study and long-term prognosis after surgical resection in 12 patients].
    Fekete F; Belghiti J; Flejou JF; Panis Y; Molas G
    Chirurgie; 1990; 116(8-9):730-4. PubMed ID: 1717205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of remission in hepatocellular carcinoma with doxorubicin.
    Johnson PJ; Williams R; Thomas H; Sherlock S; Murray-Lyon IM
    Lancet; 1978 May; 1(8072):1006-9. PubMed ID: 76932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy.
    Pompili M; Rapaccini GL; Covino M; Pignataro G; Caturelli E; Siena DA; Villani MR; Cedrone A; Gasbarrini G
    Cancer; 2001 Jul; 92(1):126-35. PubMed ID: 11443618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the clinical characteristics among hepatocellular carcinoma of hepatitis B, hepatitis C and non-B non-C patients.
    Dohmen K; Shigematsu H; Irie K; Ishibashi H
    Hepatogastroenterology; 2003; 50(54):2022-7. PubMed ID: 14696457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival.
    Stuart KE; Anand AJ; Jenkins RL
    Cancer; 1996 Jun; 77(11):2217-22. PubMed ID: 8635087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.